RxDoctor Payments Data

Kathleen Sheridan, DO

Infectious Disease · Pittsburgh, PANPI 1659540698

Payments from drug & device makers

$2,188in general payments, 2019–2025

Across 102 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$385
  • Paratek Pharmaceuticals, Inc.$354
  • Insmed, Inc.$345
  • AbbVie$230
  • Astellas Pharma US Inc$203
  • Cumberland Pharmaceuticals, Inc.$130
  • plus $540 from 11 others

What the payments were for

  • Food & beverage$2,05894%
  • Education$1306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,188 in reported general payments places this provider in the 75th percentile of 457 infectious disease providers in Pennsylvania.

See all infectious disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$232,699
Medicare patients
332
Services billed
27,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AbrysvoRsv Vacc, Pref A And Pref B/Pf13,925$4,157,638
ShingrixVaricella-Zoster Ge/As01b/Pf7,455$1,556,881
Boostrix TdapDiphth,pertuss(Acell),tet Vac3,320$214,759
TriumeqAbacavir/Dolutegravir/Lamivudi13$55,274
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$50,390
BiktarvyBictegrav/Emtricit/Tenofov Ala13$50,158
ArexvyRsvpref3 Antigen/As01e/Pf130$38,345
TwinrixHepatitis A And B Vaccine/Pf151$21,027
VaqtaHepatitis A Virus Vaccine/Pf168$16,143
Meropenem14$8,413
Ampicillin Sodium55$7,776
Daptomycin11$4,827
Typhim ViTyphoid Vi Polysacch Vaccine32$4,723
CeftriaxoneCeftriaxone Sodium43$3,258
MenquadfiMening Vac A,c,y,w135,c-Tet/Pf18$3,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq$17$55,27413 claims
GileadBiktarvy$96$50,15813 claims
MerckVaqta$385$16,143168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 457 infectious disease providers in Pennsylvania.

Other infectious disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →